Kenya is preparing to establish its first Biopharma Life Sciences Park at Konza Technopolis, a pharmaceutical and biotechnology manufacturing hub meant to reduce the country’s dependence on imported medicines and strengthen its position as a regional healthcare manufacturing center, although the project is still at the study stage.
The latest step came with Apifa Biotech, a subsidiary of API for Africa (APIFA), a pan-African company focused on essential medicines and active pharmaceutical ingredients, announcing that it had secured grant funding from Swedfund, Sweden’s development finance institution, to study the case for the park. No construction or financing has been announced, since the study has to come first.
The project is structured as a public-private partnership with the Technopolis Development Authority, which the National Treasury cleared in April 2026 to proceed to the development phase. A consortium of JLL and IQVIA has been picked to run the feasibility study, which will test the park’s technical requirements, commercial viability, investment structure and implementation roadmap before the project advances to later development stages.
At Konza, Apifa wants to design, finance, and develop a park hosting manufacturers, researchers, and investors. Invest Kenya describes a 200-acre site targeting seven to ten major pharmaceutical companies, with a project value of US$217 million (KES 28.21 billion).
Speaking on the project, Technopolis Development Authority CEO John Paul Okwiri said:
“The Biopharma Life Sciences Park will position Konza as an emerging center for life sciences and pharmaceutical manufacturing, helping Kenya move from importing most of its medicines to producing them locally.”
The ambition looks large beside the numbers, with the Ministry of Health putting the country’s pharmaceutical supply gap at about 70% earlier this year and Kenya’s policy target being to make at least half of its essential health products locally, so the first park of its kind is being asked to help flip the balance of a market that currently leans heavily on imports.
Implications for Konza
Konza could gain a credible anchor tenant and a stronger cluster identity. Pharmaceutical manufacturers, laboratories, packaging firms, cold-chain operators, and investors would have a reason to locate there, improving land take-up as each new participant makes the site more useful to the next.
The Biopharma Life Sciences Park could also validate Konza’s science-park proposition, since biopharma would test its innovation pitch by linking universities, researchers, regulators, and manufacturers in a way a conventional industrial estate cannot.
A park model can bring recurring lease, utility, and service income too, along with outside validation from Swedfund and upgrades to power, water, roads, and connectivity that could benefit the wider technopolis.
Risks and Constraints
The main risk is execution, since Konza’s PPP pipeline shows many projects in preparation and far fewer at financial close, so the Biopharma Life Sciences Park will be judged on what follows the study, from published feasibility findings and land and utility commitments to approvals, named tenants and signed financing.
A pharmaceutical park cannot rely on real estate incentives alone, because tenants will need predictable procurement, timely product registration, GMP-compliant facilities, efficient customs handling, and skilled operators. Without them, the site could become a high-cost estate with underused laboratories.
Water, waste, and environmental performance will also be important, with process water, hazardous-material handling, and effluent treatment needing to be included in the park’s capital model from the start rather than being left to tenants.
READ: Why Konza Technopolis Has Struggled to Win Global Tech Investors
For Kenya’s pharmaceutical industry, its significance will ultimately depend on the products manufactured, the investment secured and the extent to which local production becomes commercially sustainable.
The feasibility study is expected to establish the technical requirements, commercial viability, investment structure and implementation roadmap before the project advances to subsequent development stages.
